Clinical trial
Cardiac Autonomic Neuromodulation in Myocardial Revascularization (CALM): A Multicenter Randomized Controlled Trial of Partial Cardiac Denervation for the Prevention of Postoperative Atrial Fibrillation After Coronary Artery Bypass Grafting
NCT07918781 is registered in ClinicalTrials.gov with China National Center for Cardiovascular Diseases as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- Cardiac Autonomic Neuromodulation in Myocardial Revascularization (CALM): A Multicenter Randomized Controlled Trial of Partial Cardiac Denervation for the Prevention of Postoperative Atrial Fibrillation After Coronary Artery Bypass Grafting
- Lead sponsor
- China National Center for Cardiovascular Diseases
- Phase
- Not applicable
- Overall status
- Not yet recruiting
- Start date
- December 1, 2026
- Completion date
- December 31, 2030
- Enrollment
- 1,470 (estimated)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.
coronary artery disease, postoperative atrial fibrillation
Arms
As registered; 2 arms.
-
Control group
CABG alone
-
Intervention group
Partial cardiac denervation + CABG. Partial cardiac denervation consists of transection of the ligament of Marshall and resection of the Waterston fat pad.
Primary endpoints
Registered primary outcome measures; 2 primary.
-
Incidence of Postoperative Atrial Fibrillation Within 6 Postoperative Days
The proportion of participants with documented new-onset postoperative atrial fibrillation (POAF). POAF is defined as an episode of atrial fibrillation characterized by irregularly irregular RR intervals and the absence of discernible P waves, lasting more than 30 seconds. Continuous electrocardiographic recordings will be centrally reviewed by the blinded ECG Core Laboratory.
-
Time to First Occurrence of the Composite Clinical Outcome
Time from surgery to the first occurrence of any component of the composite outcome, including all-cause death, stroke, systemic embolism, myocardial infarction, readmission for cardiac reasons, or post-discharge atrial fibrillation. Suspected clinical events will be adjudicated by an independent Clinical Event Adjudication Committee blinded to treatment allocation. Post-discharge atrial fibrillation events will be reviewed by the blinded ECG Core Laboratory.
Lead sponsor's other trials
China National Center for Cardiovascular Diseases, most recent start first.
+264 more trials See the organization page
Similar trials
Same condition (Coronary Artery Disease) and phase, most recent start first.
+1,716 more trials See the condition page